AstraZeneca Reports Solid Q2 2026 Results with 5% Revenue Growth Despite Farxiga Exclusivity Loss and China VBP Headwinds
Company

AstraZeneca Reports Solid Q2 2026 Results with 5% Revenue Growth Despite Farxiga Exclusivity Loss and China VBP Headwinds

CompanyDrug

Alexion’s Ultomiris Fails to Meet Primary Endpoint in Phase III HSCT-TMA Trial Despite Showing Treatment Benefit Trend

CompanyDrug

Sanofi Halts Amlitelimab Development in Atopic Dermatitis Despite Positive Long-Term Safety Data

Roche's Susvimo Receives CHMP Recommendation for Neovascular AMD with Contivue Implant Delivery System
CompanyDrug

Roche’s Susvimo Receives CHMP Recommendation for Neovascular AMD with Contivue Implant Delivery System

CompanyDeals

Home Control International Partners with Articura on Localized Healthcare AI Infrastructure in Indonesia

Sino Biopharmaceutical and Tempo Scan Form JV to Commercialize Innovative Drugs in Indonesia
CompanyDeals

Sino Biopharmaceutical and Tempo Scan Form JV to Commercialize Innovative Drugs in Indonesia

CompanyDrug

Sichuan Biokin’s HER2 ADC T-Bren Enters Phase III Trial for Biliary Tract Cancer After Platinum Failure

Gilead's Trodelvy Receives Positive CHMP Opinion for First-Line TNBC Treatment in Combination with Keytruda
CompanyDrug

Gilead’s Trodelvy Receives Positive CHMP Opinion for First-Line TNBC Treatment in Combination with Keytruda

CompanyDrug

Walvax Biotechnology’s Bivalent HPV Vaccine WALRINVAX Gains Tanzanian Approval Following WHO Prequalification

CompanyDrug

Kanghong Pharmaceutical Secures NMPA Approval for KHN921 Gene Therapy in MYBPC3-Related Hypertrophic Cardiomyopathy Following U.S. FDA Clearance

CompanyDrug

Changchun High-Tech Subsidiary GeneScience Files SLE Clinical Application for Novel Dual-Target BAFF/APRIL Inhibitor GenSci136

CompanyDrug

Lilly’s Retatrutide Delivers Up to 22.6% Weight Loss in Phase 3 Trials, Establishing Triple Agonist Leadership in Obesity Market